These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 12045315)

  • 41. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia.
    Citrome L; Volavka J; Czobor P; Sheitman B; Lindenmayer JP; McEvoy J; Cooper TB; Chakos M; Lieberman JA
    Psychiatr Serv; 2001 Nov; 52(11):1510-4. PubMed ID: 11684748
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Olanzapine and risperidone.
    Love RC; Kelly DL
    Am J Health Syst Pharm; 2003 Mar; 60(5):487-8; author reply 488-9. PubMed ID: 12635459
    [No Abstract]   [Full Text] [Related]  

  • 43. Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia.
    Bitter I; Dossenbach MR; Brook S; Feldman PD; Metcalfe S; Gagiano CA; Füredi J; Bartko G; Janka Z; Banki CM; Kovacs G; Breier A;
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):173-80. PubMed ID: 14687871
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Weight gain and antipsychotic medications.
    Aquila R; Emanuel M
    J Clin Psychiatry; 1999 May; 60(5):336-7. PubMed ID: 10362443
    [No Abstract]   [Full Text] [Related]  

  • 45. Clinical trial response and dropout rates with olanzapine versus risperidone.
    Santarlasci B; Messori A
    Ann Pharmacother; 2003 Apr; 37(4):556-63. PubMed ID: 12659615
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Viewpoint of schizophrenic patients: a European survey].
    Courtet P
    Encephale; 2001; 27(1):28-38. PubMed ID: 11294036
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia.
    Conley RR; Tamminga CA; Bartko JJ; Richardson C; Peszke M; Lingle J; Hegerty J; Love R; Gounaris C; Zaremba S
    Am J Psychiatry; 1998 Jul; 155(7):914-20. PubMed ID: 9659857
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial.
    Sikich L; Hamer RM; Bashford RA; Sheitman BB; Lieberman JA
    Neuropsychopharmacology; 2004 Jan; 29(1):133-45. PubMed ID: 14583740
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A retrospective comparison of cumulative time spent in remission during treatment with olanzapine or risperidone among patients with schizophrenia.
    Sethuraman G; Taylor CC; Enerson M; Dunayevich E
    Schizophr Res; 2005 Nov; 79(2-3):337-40. PubMed ID: 16054802
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Risperidone side effects.
    Conley RR
    J Clin Psychiatry; 2000; 61 Suppl 8():20-3; discussion 24-5. PubMed ID: 10811239
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Atypical antipsychotics and cardiovascular risk in schizophrenic patients.
    Bouchard RH; Demers MF; Simoneau I; Alméras N; Villeneuve J; Mottard JP; Cadrin C; Lemieux I; Després JP
    J Clin Psychopharmacol; 2001 Feb; 21(1):110-1. PubMed ID: 11199934
    [No Abstract]   [Full Text] [Related]  

  • 52. Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis.
    Taylor DM; Wright T; Libretto SE;
    J Clin Psychiatry; 2003 May; 64(5):589-97. PubMed ID: 12755664
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A retrospective economic evaluation of olanzapine versus risperidone in the treatment of schizophrenia.
    Zhao Z
    Manag Care Interface; 2002 Feb; 15(2):75-81. PubMed ID: 11875967
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.
    Stroup TS; Lieberman JA; McEvoy JP; Swartz MS; Davis SM; Capuano GA; Rosenheck RA; Keefe RS; Miller AL; Belz I; Hsiao JK;
    Am J Psychiatry; 2007 Mar; 164(3):415-27. PubMed ID: 17329466
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Risperidone and olanzapine: optimal dosing for efficacy and tolerability in patients with schizophrenia.
    Kasper S
    Int Clin Psychopharmacol; 1998 Nov; 13(6):253-62. PubMed ID: 9861575
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia.
    Keck PE; Strakowski SM; McElroy SL
    J Clin Psychiatry; 2000; 61 Suppl 3():4-9. PubMed ID: 10724127
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Benefit-risk evaluation of olanzapine, risperidone and sertindole in the treatment of schizophrenia.
    Kasper S; Hale A; Azorin JM; Möller HJ
    Eur Arch Psychiatry Clin Neurosci; 1999; 249 Suppl 2():II1-II14. PubMed ID: 10603070
    [No Abstract]   [Full Text] [Related]  

  • 58. Patients' opinions of olanzapine and risperidone following long-term treatment: results from a cross-sectional survey.
    McGrath BM; Tempier RP
    Pharmacopsychiatry; 2005 Jul; 38(4):147-57. PubMed ID: 16025416
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A cost-effectiveness clinical decision analysis model for schizophrenia.
    Palmer CS; Revicki DA; Genduso LA; Hamilton SH; Brown RE
    Am J Manag Care; 1998 Mar; 4(3):345-55. PubMed ID: 10178497
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Olanzapine appears haematologically safe in patients who developed blood dyscrasia on clozapine and risperidone.
    Dernovsek MZ; Tavcar R
    Int Clin Psychopharmacol; 2000 Jul; 15(4):237-8. PubMed ID: 10954065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.